JP2021516231A5 - - Google Patents
Info
- Publication number
- JP2021516231A5 JP2021516231A5 JP2020545351A JP2020545351A JP2021516231A5 JP 2021516231 A5 JP2021516231 A5 JP 2021516231A5 JP 2020545351 A JP2020545351 A JP 2020545351A JP 2020545351 A JP2020545351 A JP 2020545351A JP 2021516231 A5 JP2021516231 A5 JP 2021516231A5
- Authority
- JP
- Japan
- Prior art keywords
- phenyl
- compound according
- alkyl
- substituted
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862636831P | 2018-02-28 | 2018-02-28 | |
| US62/636,831 | 2018-02-28 | ||
| PCT/US2019/019936 WO2019169065A2 (en) | 2018-02-28 | 2019-02-28 | Wee1 kinase inhibitors and methods of treating cancer using the same |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021516231A JP2021516231A (ja) | 2021-07-01 |
| JP2021516231A5 true JP2021516231A5 (enExample) | 2022-03-09 |
| JP7483620B2 JP7483620B2 (ja) | 2024-05-15 |
Family
ID=67805580
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020545351A Active JP7483620B2 (ja) | 2018-02-28 | 2019-02-28 | Ｗｅｅ１キナーゼ阻害物質およびそれを使用してがんを処置する方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US12220415B2 (enExample) |
| EP (1) | EP3758706A4 (enExample) |
| JP (1) | JP7483620B2 (enExample) |
| AU (1) | AU2019227823B2 (enExample) |
| CA (1) | CA3088997A1 (enExample) |
| WO (1) | WO2019169065A2 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2016344040B2 (en) | 2015-11-01 | 2020-12-10 | The Regents Of The University Of Colorado, A Body Corporate | Wee 1 kinase inhibitors and methods of making and using the same |
| CA3070073A1 (en) | 2017-07-18 | 2019-01-24 | Nuvation Bio Inc. | 1,8-naphthyridinone compounds and uses thereof |
| JP2020527588A (ja) | 2017-07-18 | 2020-09-10 | ニューベイション・バイオ・インコーポレイテッドＮｕｖａｔｉｏｎ Ｂｉｏ Ｉｎｃ． | アデノシンアンタゴニストとしてのヘテロ環式化合物 |
| CA3078945A1 (en) | 2017-10-09 | 2019-04-18 | Nuvation Bo Inc. | Heterocyclic compounds and uses thereof |
| EP3694861A4 (en) | 2017-10-09 | 2021-05-19 | Nuvation Bio Inc. | HETEROCYCLIC COMPOUNDS AND USES THEREOF |
| CA3088997A1 (en) | 2018-02-28 | 2019-09-06 | The Regents Of The University Of Colorado, A Body Corporate | Wee1 kinase inhibitors and methods of treating cancer using the same |
| BR112020018286A2 (pt) | 2018-03-09 | 2020-12-29 | Recurium Ip Holdings, Llc | 1,2-di-hidro-3h-pirazolo[3,4-d]pirimidin-3-onas substituídas |
| US11254670B2 (en) | 2019-01-18 | 2022-02-22 | Nuvation Bio Inc. | 1,8-naphthyridinone compounds and uses thereof |
| WO2020150674A1 (en) | 2019-01-18 | 2020-07-23 | Nuvation Bio Inc. | Heterocyclic compounds as adenosine antagonists |
| JP2022526831A (ja) | 2019-04-09 | 2022-05-26 | ニューベイション・バイオ・インコーポレイテッド | ヘテロ環式化合物およびその使用 |
| CN115023229A (zh) * | 2019-12-20 | 2022-09-06 | 里科瑞尔姆Ip控股有限责任公司 | 组合 |
| BR112022012283A2 (pt) * | 2019-12-20 | 2022-08-30 | Recurium Ip Holdings Llc | Combinações |
| CN113402520A (zh) * | 2020-03-16 | 2021-09-17 | 中国科学院上海药物研究所 | Wee1蛋白降解剂 |
| AU2021290701A1 (en) * | 2020-06-17 | 2023-02-02 | Wigen Biomedicine Technology (shanghai) Co., Ltd. | Pyrazolo(3,4-d)pyrimidine-3-ketone derivative as Wee-1 inhibitor |
| JP7866564B2 (ja) * | 2021-05-28 | 2026-05-27 | 江蘇天士力帝益薬業有限公司 | Ｗｅｅ１阻害剤とその用途 |
| TW202329937A (zh) | 2021-12-03 | 2023-08-01 | 美商英塞特公司 | 雙環胺ｃｋ１２抑制劑 |
| US12084453B2 (en) | 2021-12-10 | 2024-09-10 | Incyte Corporation | Bicyclic amines as CDK12 inhibitors |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB884151A (en) | 1957-12-06 | 1961-12-06 | Ciba Ltd | New pyrazolo-pyrimidines substituted in the pyrazole nucleus, and process for their manufacture |
| WO2006091737A1 (en) | 2005-02-24 | 2006-08-31 | Kemia, Inc. | Modulators of gsk-3 activity |
| PE20080695A1 (es) * | 2006-04-27 | 2008-06-28 | Banyu Pharma Co Ltd | Derivados de dihidropirazolopirimidinona como inhibidores de quinasa weel |
| RU2011141121A (ru) * | 2009-03-11 | 2013-04-20 | Окленд Юнисервисиз Лимитед | Пролекарственные формы ингибиторов киназ и их применение в терапии |
| BR112012004720B1 (pt) | 2009-09-02 | 2021-06-29 | Auckland Uniservices Limited | Inibidores de cinase, seus usos, profármaco e composição farmacêutica que o compreende |
| GB201322602D0 (en) | 2013-12-19 | 2014-02-05 | Almac Discovery Ltd | Pharmaceutical compounds |
| AU2016344040B2 (en) * | 2015-11-01 | 2020-12-10 | The Regents Of The University Of Colorado, A Body Corporate | Wee 1 kinase inhibitors and methods of making and using the same |
| AU2018209006B2 (en) | 2017-01-22 | 2021-04-22 | Sunshine Lake Pharma Co., Ltd. | Thienopyrimidine derivative and use thereof in medicine |
| JP6717457B2 (ja) | 2017-01-23 | 2020-07-01 | シージャーズォアン サガシティ ニュー ドラッグ デベロップメント カンパニー リミテッド | Ｗｅｅ１阻害剤としての１，２−ジヒドロ−３Ｈ−ピラゾロ［３，４−ｄ］ピリミジン−３−オン誘導体 |
| MX2020001235A (es) | 2017-08-01 | 2020-07-20 | Recurium Ip Holdings Llc | Análogos de 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-ona. |
| CA3088997A1 (en) | 2018-02-28 | 2019-09-06 | The Regents Of The University Of Colorado, A Body Corporate | Wee1 kinase inhibitors and methods of treating cancer using the same |
-
2019
- 2019-02-28 CA CA3088997A patent/CA3088997A1/en active Pending
- 2019-02-28 JP JP2020545351A patent/JP7483620B2/ja active Active
- 2019-02-28 EP EP19760397.0A patent/EP3758706A4/en not_active Withdrawn
- 2019-02-28 US US16/975,818 patent/US12220415B2/en active Active
- 2019-02-28 WO PCT/US2019/019936 patent/WO2019169065A2/en not_active Ceased
- 2019-02-28 AU AU2019227823A patent/AU2019227823B2/en active Active
-
2024
- 2024-12-20 US US18/991,248 patent/US20250186447A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2101759B1 (en) | Methods of using mek inhibitors | |
| RU2021103727A (ru) | Фармацевтические композиции и способы борьбы с кардиотоксичностью, вызванной химиотерапией | |
| CN107406417A (zh) | 4H‑吡咯并[3,2‑c]吡啶‑4‑酮衍生物 | |
| US20190142812A1 (en) | 5-substituted 2-(morpholin-4-yl)-1,7-naphthyridines | |
| JP2012501312A5 (enExample) | ||
| US20190225593A1 (en) | Substituted chromane-8-carboxamide compounds and analogues thereof, and methods using same | |
| JP2015530975A5 (enExample) | ||
| WO2018122168A1 (en) | Combinations of bub1 kinase and parp inhibitors | |
| JP2013501790A5 (enExample) | ||
| JP2017502967A5 (enExample) | ||
| JP2020507606A5 (enExample) | ||
| JP2021524844A5 (enExample) | ||
| RU2012147511A (ru) | Применение ингибиторов c-src в комбинации с пиримидиламинобензамидом для лечения лейкоза | |
| KR20120099650A (ko) | Ｂｃｒ-ａｂｌ, ｃ-ｋｉｔ, ｄｄｒ1, ｄｄｒ2 또는 ｐｄｇｆ-ｒ 키나제 활성에 의해 매개된 증식성 장애 및 다른 병적 상태의 치료 방법 | |
| CA2526989A1 (en) | Hydroxyamidine and hydroxyguanidine compounds as urokinase inhibitors | |
| KR20080004495A (ko) | 암을 치료하기 위한 조합물, 방법 및 조성물 | |
| WO2016205460A4 (en) | Polycyclic derivatives targeting ral gtpases and their therapeutical applications | |
| JP2018519332A5 (enExample) | ||
| WO2016087490A1 (en) | Combination of pi3k-inhibitors | |
| CA2553704A1 (en) | Substituted benzimidazoles and their use for inducing apoptosis | |
| RU2382784C2 (ru) | Новые пиперидинзамещенные диаминотиазолы | |
| RU2008127264A (ru) | Производные пиримидиламинобензамида, предназначенные для лечения нейрофиброматоза | |
| JP2022550040A5 (enExample) | ||
| US12303508B2 (en) | Combinatory treatment strategies of cancer based on RNA polymerase I inhibition | |
| US20210369724A1 (en) | Combination of atr kinase inhibitors with 2,3-dihydroimidazo[1,2-c]quinazoline compounds |